Penserra Capital Management LLC Purchases New Stake in Insulet Corporation $PODD

Penserra Capital Management LLC bought a new stake in Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 216 shares of the medical instruments supplier’s stock, valued at approximately $67,000.

Several other institutional investors also recently modified their holdings of the business. Golden State Wealth Management LLC boosted its holdings in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares during the last quarter. Andra AP fonden increased its stake in shares of Insulet by 167.9% in the 2nd quarter. Andra AP fonden now owns 57,600 shares of the medical instruments supplier’s stock valued at $18,097,000 after acquiring an additional 36,100 shares during the last quarter. Resona Asset Management Co. Ltd. raised its position in shares of Insulet by 7.6% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 25,589 shares of the medical instruments supplier’s stock valued at $8,034,000 after acquiring an additional 1,803 shares during the period. EFG Asset Management North America Corp. boosted its stake in Insulet by 27.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 9,883 shares of the medical instruments supplier’s stock worth $3,105,000 after acquiring an additional 2,130 shares during the last quarter. Finally, Ellevest Inc. bought a new position in Insulet during the 2nd quarter worth approximately $217,000.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PODD. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Truist Financial boosted their target price on Insulet from $365.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Piper Sandler increased their price target on Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Finally, BTIG Research reaffirmed a “buy” rating and set a $370.00 price target on shares of Insulet in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $374.10.

Insulet Stock Performance

PODD opened at $332.67 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business’s 50-day simple moving average is $323.89 and its 200 day simple moving average is $311.52. The firm has a market capitalization of $23.40 billion, a PE ratio of 101.12, a PEG ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $353.50.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period in the prior year, the firm posted $1.08 earnings per share. The company’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.